UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                             CURRENT REPORT Pursuant
                          to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

  Date of report (Date of earliest event reported): November 3, 2004

                            SANGAMO BIOSCIENCES, INC.
--------------------------------------------------------------------------------
             (Exact Name of Registrant as Specified in Its Charter)

                                    Delaware
--------------------------------------------------------------------------------
                 (State or Other Jurisdiction of Incorporation)

            000-30171                                    68-0359556
--------------------------------------------------------------------------------
     (Commission File Number)                  (IRS Employer Identification No.)

       501 Canal Blvd, Suite A100                    Richmond, California 94804
--------------------------------------------------------------------------------
 (Address of Principal Executive Offices)                    (Zip Code)

                                 (510) 970-6000
--------------------------------------------------------------------------------
              (Registrant's Telephone Number, Including Area Code)

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

      Check the  appropriate  box below if the Form 8-K  filing is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))



Item 2.02. Results of Operations and Financial Condition.

      On November 3, 2004,  Sangamo  BioSciences,  Inc.  issued a press  release
announcing its financial results for the quarter and nine months ended September
30,  2004.  A copy of the press  release is  attached  as  Exhibit  99.1 to this
Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits

(c)  Exhibits.  The  following  material is filed as an exhibit to this  Current
Report on Form 8-K:

Exhibit No.
99.1               Press Release Issued November 3, 2004.



SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

 DATE: November 3, 2004

                                             SANGAMO BIOSCIENCES, INC.

                                             By: /s/ EDWARD O. LANPHIER II
                                                 -------------------------------
                                                 Edward O. Lanphier II
                                                 President, Chief Executive
                                                 Officer